Synlogic (SYBX) Tops Q2 EPS by 2c
Get Alerts SYBX Hot Sheet
Join SI Premium – FREE
Synlogic (NASDAQ: SYBX) reported Q2 EPS of ($0.44), $0.02 better than the analyst estimate of ($0.46).
"Our team at Synlogic continues to achieve our clinical programs and platform milestones, driving the advancement of our portfolio of novel Synthetic Biotic medicines," said Aoife Brennan, M.B. Ch.B., Synlogic's president and chief executive officer. "We are on track to initiate the Phase 2 study of SYNB1618 in Phenylketonuria and the monotherapy arm of our Phase 1 trial of SYNB1891 in solid tumors continues to progress as planned. With the advancement of our pipeline and a cash runway into 2022, we are well positioned to meet our objectives and bring these novel Synthetic Biotic medicines to patients."
"We have rapidly advanced SYNB8802 in Enteric Hyperoxaluria, which leads to dangerously high levels of urinary oxalate and for which patients have few treatment options today," said Richard Riese, M.D., Synlogic's chief medical officer. "We look forward to an IND filing and moving SYNB8802 into the clinic in early 2021."
For earnings history and earnings-related data on Synlogic (SYBX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Volcon (VLCN) Reports 2023 Operational and Financial Results
- Midday movers: RH, Estee Lauder rise; Tesla falls
- Achieve Life Sciences (ACHV) Tops Q4 EPS by 5c
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!